SCHEMBL5545173

SCHEMBL5545173

O=[C]OCCc1cc2cc(Cl)ccc2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.44
CYP19A1 P11511 1/20 0.43
GPR35 Q9HC97 2/20 0.42
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
ADAM17 P78536 1/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
KMT2A Q03164 1/20 0.38
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
TSHR P16473 1/20 0.37
F2 P00734 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542090 0.89 MAOB (0.40) MAOBCYP19A1GPR35KDM4EALDH1A1
SCHEMBL5544549 0.88 CA12 (0.38) MAOBCYP19A1GPR35CYP1A2CA12
SCHEMBL5542277 0.82 CA12 (0.38) CYP2C9L3MBTL1CA1CA2CA12
SCHEMBL28441816 0.79 MAOB (0.44) MAOBCYP19A1GPR35KDM4EALDH1A1
SCHEMBL5541624 0.78 DRD3 (0.36) MAOBCA12CA9
SCHEMBL11190838 0.74 CYP19A1 (0.49) MAOBCYP19A1GPR35KDM4EALDH1A1
SCHEMBL8717811 0.74 CYP19A1 (0.49) MAOBCYP19A1GPR35KDM4EALDH1A1
SCHEMBL8895618 0.74 MMP2 (0.50) MAOBCYP19A1GPR35KDM4EALDH1A1
SCHEMBL8895635 0.74 MAOB (0.47) MAOBCYP19A1GPR35KDM4EALDH1A1
SCHEMBL5541845 0.73 L3MBTL1 (0.36) KDM4EALDH1A1L3MBTL1CA1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAOB 2140/4885CYP19A1 3120/4885GPR35 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.